The global gamma knife market is estimated to be valued at US$ 239.1 billion in 2023 and is expected to exhibit a CAGR of 5.4% during the forecast period (2023-2030).
Analysts’ Views on Global Gamma Knife Market:
Gamma knife radiosurgery is a type of radiation therapy. It can be used to treat tumors, veins that have developed differently than usual, and other differences in the brain. Increasing product approvals from regulatory authorities are expected to drive the global gamma knife market over the forecast period. For instance, in October 2022, Elekta, a neuroscience company, received U.S. Food and Drug Administration 510(k) clearance for Elekta Esprit, a new Leksell Gamma Knife radiosurgery platform. This system is available to clinicians and people with brain disease in the U.S. Leksell Gamma Knife has been designed as a gentler alternative to open surgery and conventional radiotherapy.
Figure 1. Global Gamma Knife Market Share (%), By Indication, 2023
To learn more about this report, Request sample copy
Global Gamma Knife Market– Drivers
Figure 2. Global Gamma Knife Market Share (%), By Region, 2023
To learn more about this report, Request sample copy
Global Gamma Knife Market- Regional Analysis
Among regions, North America is estimated to hold a dominant position in the global gamma knife market over the forecast period. North America is estimated to hold 33.5% of the market share in 2023. The global gamma knife market is expected to witness significant growth in the coming years, driven increasing prevalence of neurological disorders is contributing to the growth of the gamma knife market in the North America region. For instance, according to the American Neurological Association (ANA) in March 2021, neurological diseases affect around 100 billion people in the U.S. This significant number of patients with one neurological disorder is expected to increase the number of neurosurgeries in the U.S., thereby driving demand for gamma knife in the U.S.
Global Gamma Knife Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.
COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, the U.A.E., Egypt, and others, are facing problems with the transportation of things from one place to another.
For instance, according to the research study published in August 2020, titled “Overall Impact of the COVID-19 Pandemic on Interventional Radiology Services: A Canadian Perspective”, the COVID-19 pandemic had negatively impacted the interventional radiology services in Canada, especially for elective cases, and as per the study, about 49.3% of the respondents reported that there was an overall decline in interventional radiology services in the country.
Gamma Knife Market Report Coverage
Report Coverage | Details | ||
---|---|---|---|
Base Year: | 2022 | Market Size in 2023: | US$ 239.1 Bn |
Historical Data for: | 2018 to 2022 | Forecast Period: | 2023 to 2030 |
Forecast Period 2023 to 2030 CAGR: | 5.4% | 2030 Value Projection: | US$ 345.6 Bn |
Geographies covered: |
|
||
Segments covered: |
|
||
Companies covered: |
Elekta, American Radiosurgery Inc., Masep Medical Science & Technology Development Co., Ltd., Panacea Medical Technologies Pvt. Ltd., Nordion (Canada) Inc. |
||
Growth Drivers: |
|
||
Restraints & Challenges: |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Global Gamma Knife Market Segmentation:
The global gamma knife market report is segmented by indication, by anatomy, by end user, and by region.
Global Gamma Knife Market- Cross Sectional Analysis:
Increasing prevalence of head and neck cancer in North America is also expected to boost demand gamma knife market in North America region. For instance, according to the American Society of Clinical Oncology (ASCO), in January 2021, head and neck cancer accounted for about 4% of all cancers in the United States. In 2020, an estimated 66,630 people (48,740 men and 17,890 women) had developed head and neck cancer, and also estimated that 14,620 deaths from head and neck cancer in 2020. Thus, this constantly increasing head and neck cancer will help in the growth of the market.
Global Gamma Knife Market: Key Developments
In October 2022, Elekta collaborated with Brainlab a medical technology company to enable neurosurgeons and radiation oncologists to use Brainlab’s iPlan software together with Elekta’s Leksell GammaPlan treatment planning for Gamma Knife radiosurgery. Through this collaboration, clinicians will be given the option to add the functionality of iPlan RT Image to the optimized dosimetry and precision of Leksell GammaPlan treatment planning.
In October 2021, Panacea Medical Technologies Pvt. Ltd. a medical equipment company received U.S. Food and Drug Administration (FDA) 510(k) clearance for its next generation stereotactic body radiotherapy (SBRT)-enabled linear accelerator on a ring gantry platform.
Global Gamma Knife Market: Key Trends
Global Gamma Knife Market: Restraint
Global Gamma Knife Market - Key Players
Major players operating in the global gamma knife market include Elekta, American Radiosurgery Inc., and Masep Medical Science & Technology Development Co., Ltd., Panacea Medical Technologies Pvt. Ltd., and Nordion (Canada) Inc.
*Definition: Gamma knife is an advanced radiation therapy used for the treatment of cancer among adults and children of all ages. It is basically a beam of highly focused gamma rays used for precisely cutting or destroying tumors or damaged cells in the brain. Gamma knife uses tiny beams of radiation for the treatment of tumor and carcinogenic region of thre body. It is most often used in the treatment of neurological conditions such as brain metastases, acoustic neuroma and trigeminal neuralgia.
Share
About Author
Manisha Vibhute is a consultant with over 5 years of experience in market research and consulting. With a strong understanding of market dynamics, Manisha assists clients in developing effective market access strategies. She helps medical device companies navigate pricing, reimbursement, and regulatory pathways to ensure successful product launches.
Learn more about Manisha VibhuteMissing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Select a License Type
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients